Format

Send to

Choose Destination
Lancet. 2017 Oct 21;390(10105):1813-1814. doi: 10.1016/S0140-6736(17)32289-4. Epub 2017 Aug 27.

Potential efficacy of interleukin-1β inhibition in lung cancer.

Author information

1
Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, and Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Clayton, VIC 3168, Australia. Electronic address: brendan.jenkins@hudson.org.au.
PMID:
28855076
DOI:
10.1016/S0140-6736(17)32289-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center